AnHorn Medicines Advances AH-008 into Phase I Trial for CIPN Prevention
Irvine, California, USA — July 27, 2026 July 27, 2026 – AnHorn Medicines has announced the successful first subject...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Irvine, California, USA — July 27, 2026 July 27, 2026 – AnHorn Medicines has announced the successful first subject...
BOSTON – July 24, 2026 Zevra Therapeutics, Inc. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
CAMBRIDGE, Mass., United States – May 5, 2026 Amylyx Pharmaceuticals Inc. has announced the launch of a U.S. Expanded...
LOS ANGELES, March 31, 2026 Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate...
LAGUNA HILLS, Calif., March 19, 2026 Adagio Medical Holdings, Inc. announced successful outcomes from Expanded Access Program (EAP) cases...
ROSWELL, Ga., September 8, 2025 — Saol Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has...
